Cargando…

Ligands stimulating antitumour immunity as the next G-quadruplex challenge

G-quadruplex (G4) binders have been investigated to discover new anticancer drugs worldwide in past decades. As these ligands are generally not highly cytotoxic, the discovery rational was mainly based on increasing the cell-killing potency. Nevertheless, no G4 binder has been shown yet to be effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Giulia, Marinello, Jessica, Russo, Marco, Capranico, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482198/
https://www.ncbi.nlm.nih.gov/pubmed/36114513
http://dx.doi.org/10.1186/s12943-022-01649-y
_version_ 1784791400622063616
author Miglietta, Giulia
Marinello, Jessica
Russo, Marco
Capranico, Giovanni
author_facet Miglietta, Giulia
Marinello, Jessica
Russo, Marco
Capranico, Giovanni
author_sort Miglietta, Giulia
collection PubMed
description G-quadruplex (G4) binders have been investigated to discover new anticancer drugs worldwide in past decades. As these ligands are generally not highly cytotoxic, the discovery rational was mainly based on increasing the cell-killing potency. Nevertheless, no G4 binder has been shown yet to be effective in cancer patients. Here, G4 binder activity at low dosages will be discussed as a critical feature to discover ligands with therapeutic effects in cancer patients. Specific effects of G4 binders al low doses have been reported to occur in cancer and normal cells. Among them, genome instability and the stimulation of cytoplasmic processes related to autophagy and innate immune response open to the use of G4 binders as immune-stimulating agents. Thus, we propose a new rational of drug discovery, which is not based on cytotoxic potency but rather on immune gene activation at non-cytotoxic dosage.
format Online
Article
Text
id pubmed-9482198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94821982022-09-18 Ligands stimulating antitumour immunity as the next G-quadruplex challenge Miglietta, Giulia Marinello, Jessica Russo, Marco Capranico, Giovanni Mol Cancer Review G-quadruplex (G4) binders have been investigated to discover new anticancer drugs worldwide in past decades. As these ligands are generally not highly cytotoxic, the discovery rational was mainly based on increasing the cell-killing potency. Nevertheless, no G4 binder has been shown yet to be effective in cancer patients. Here, G4 binder activity at low dosages will be discussed as a critical feature to discover ligands with therapeutic effects in cancer patients. Specific effects of G4 binders al low doses have been reported to occur in cancer and normal cells. Among them, genome instability and the stimulation of cytoplasmic processes related to autophagy and innate immune response open to the use of G4 binders as immune-stimulating agents. Thus, we propose a new rational of drug discovery, which is not based on cytotoxic potency but rather on immune gene activation at non-cytotoxic dosage. BioMed Central 2022-09-17 /pmc/articles/PMC9482198/ /pubmed/36114513 http://dx.doi.org/10.1186/s12943-022-01649-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Miglietta, Giulia
Marinello, Jessica
Russo, Marco
Capranico, Giovanni
Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title_full Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title_fullStr Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title_full_unstemmed Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title_short Ligands stimulating antitumour immunity as the next G-quadruplex challenge
title_sort ligands stimulating antitumour immunity as the next g-quadruplex challenge
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482198/
https://www.ncbi.nlm.nih.gov/pubmed/36114513
http://dx.doi.org/10.1186/s12943-022-01649-y
work_keys_str_mv AT migliettagiulia ligandsstimulatingantitumourimmunityasthenextgquadruplexchallenge
AT marinellojessica ligandsstimulatingantitumourimmunityasthenextgquadruplexchallenge
AT russomarco ligandsstimulatingantitumourimmunityasthenextgquadruplexchallenge
AT capranicogiovanni ligandsstimulatingantitumourimmunityasthenextgquadruplexchallenge